Key result
Hydroxychloroquine use is linked to an absolute ~23-point reduction in SLE patients with dyslipidemia.
Why the study?
The effects of hydroxychloroquine on lipid metabolism have not been consistent across diseases and ethnic populations, and evidence regarding its effects on serum lipid levels in Japanese patients with systemic lupus erythematosus is limited.
Does hydroxychloroquine improve serum lipid parameters at 1 year in Japanese patients with systemic lupus erythematosus?
Cohort (n=435)
No
Does hydroxychloroquine improve serum lipid parameters at 1 year in Japanese patients with systemic lupus erythematosus?
In Japanese patients with systemic lupus erythematosus, hydroxychloroquine use was associated with significant improvements in serum triglycerides, HDL-C, and LDL-C at 1 year, independent of glucocorticoid dose reduction.
Answers are grounded in this paper and cite their sources.
May support lipid management in SLE; leaves open whether this reduces cardiovascular events in randomized trials.
Background Systemic lupus erythematosus (SLE) is associated with lipid metabolism abnormalities arising from both disease activity and glucocorticoid therapy, contributing to an elevated risk of cardiovascular events and requiring rigorous lipid management. In recent years, hydroxychloroquine (HCQ), a therapeutic agent for SLE, has been suggested to affect lipid metabolism in patients with autoimmune disease. However, its effects on lipid metabolism have not been consistent across diseases and ethnic populations, and evidence regarding the effects of HCQ on lipid metabolism in Japanese patients with SLE are limited. This study aimed to evaluate the effects of HCQ on serum lipid levels in Japanese patients with SLE. Methods This study involved 435 patients with SLE treated at a single center between October 2015 and January 2025. After propensity score matching, 198 patients (99 in each group) were analyzed to compare the changes in serum lipid parameters over a 1-year follow-up period between the HCQ and non-HCQ groups. As a stratified analysis, changes in serum lipid parameters were compared according to the glucocorticoid dose reduction during the 1-year follow-up period. In addition, the proportion of patients with at least one lipid abnormality, as defined by the 2022 Japan Atherosclerosis Society guidelines, was assessed at baseline and at 1 year, and odds ratios (ORs) for individual lipid abnormalities at 1 year were calculated using the non-HCQ group as the reference. Results The HCQ group showed significant improvements in serum triglyceride (TG), high-density lipoprotein cholesterol (HDL-C), and low-density lipoprotein cholesterol (LDL-C) levels compared to the non-HCQ group. These findings were consistent with those of a stratified analysis of patients without glucocorticoid dose reduction. The proportion of patients with at least one lipid abnormality decreased from 35% at baseline to 12% at 1 year in the HCQ group, whereas it increased from 34% to 39% in the non-HCQ group. At 1 year, HCQ use was associated with lower odds of hypertriglyceridemia and high LDL-C than non-HCQ use. Conclusions HCQ use may be a novel therapeutic approach for lipid management in patients with SLE, potentially improving their prognosis.
No takes yet. Share an insight, caveat, or question.
Wakai et al. (2026) conducted a cohort in Systemic lupus erythematosus (SLE) (n=435). Hydroxychloroquine vs. No hydroxychloroquine (non-HCQ group) was evaluated on Changes in serum lipid parameters (TG, HDL-C, LDL-C) and proportion of patients with at least one lipid abnormality at 1 year. Hydroxychloroquine use reduced the proportion of SLE patients with at least one lipid abnormality from 35% to 12% at 1 year, compared to an increase from 34% to 39% in non-users.
Synapse has enriched 10 related papers. Consider them for comparative context: